Company intelligence / Profile preview

Shanghai Zhongxin Medical Technology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Zhongxin Health has provided assistance to over 6,000 cancer patients through its platform, administering over 22,000 doses of doxorubicin hydrochloride liposome and supporting over 7,000 SLE patients with free medication; patient satisfaction rates are high (over 80%)

Therapeutic areas: OncologyImmunology
Modalities: DeviceDigital (software-based patient management)Small moleculeLiposomal formulation
Industry: Non-Academic Healthcare

Partnerships

Beijing Public Health Foundation (BPHF)Over 300 hospitals and 100 pharmacies across China

Beyond the preview

Go deeper on Shanghai Zhongxin Medical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Zhongxin Medical Technology.

Explore the full profile